Predictive factors for recurrence of papillary thyroid carcinoma: analysis of 4,085 patients
Carregando...
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
PACINI EDITORE
Autores
CARVALHO, Andre Ywata de
KOHLER, Hugo Fontan
GOMES, Camila Couto
VARTANIAN, Jose Guilherme
Citação
ACTA OTORHINOLARYNGOLOGICA ITALICA, v.41, n.3, p.236-242, 2021
Resumo
Objective. The incidence of papillary thyroid carcinoma (PTC) has increased in recent years and its treatment remains controversial. The objective of this study is to identify clinicopathological predictive factors of tumour recurrence. Methods. We retrospectively analysed 4,085 patients who underwent thyroidectomy for PTC from 1996 to 2015. Patients were stratified according to American Thyroid Association (ATA) risk categories and clinicopathological features were evaluated to identify independent factors for recurrence. Results. After a mean follow-up of 58.7 (range 3-256.5) months, tumour recurrence was diagnosed in 176 (4.3%) patients, mostly in lymph nodes. Distant metastasis occurred in 18 patients (0.4%). There were 3 (0.1%) cancer-related deaths. Multivariate analysis showed that tumour size >10 mm, multifocality, extrathyroidal extension and lymph node metastasis (all, P < 0.001) were independent risk factors for recurrence. Further, recurrence was identified in 1.6% of the ATA low-risk, 7.4% of the intermediate-risk and 22.7% of the high-risk patients (P < 0.001). Conclusions. In PTC patients, tumour size >10 mm, multifocality. extrathyroidal extension and presence of lymph node metastasis as well as the ATA recurrence staging system effectively predict recurrence.
Palavras-chave
thyroid, papillary carcinoma, recurrence, survival
Referências
- Amin MB, 2017, AJCC CANC STAGING MA, P873
- Cipriani Nicole A, 2019, Surg Pathol Clin, V12, P883, DOI 10.1016/j.path.2019.07.001
- Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110
- de Carvalho AY, 2015, JAMA OTOLARYNGOL, V141, P599, DOI 10.1001/jamaoto.2015.0786
- de Matos PS, 2006, ENDOCR PATHOL, V17, P165, DOI 10.1385/EP:17:2:165
- Grogan RH, 2013, SURGERY, V154, P1436, DOI 10.1016/j.surg.2013.07.008
- HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3
- Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
- Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
- Ito Y, 2012, WORLD J SURG, V36, P1274, DOI 10.1007/s00268-012-1423-5
- Kaliszewski K, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1501-8
- Kazaure HS, 2012, ANN SURG ONCOL, V19, P1874, DOI 10.1245/s10434-011-2129-x
- Kim HJ, 2013, WORLD J SURG, V37, P376, DOI 10.1007/s00268-012-1835-2
- Lang BHH, 2013, THYROID, V23, P1087, DOI 10.1089/thy.2012.0608
- Macedo FIB, 2015, SURG ONCOL, V24, P117, DOI 10.1016/j.suronc.2015.04.005
- Mehanna H, 2014, J CLIN ENDOCR METAB, V99, P2834, DOI 10.1210/jc.2013-2118
- Nabhan F, 2017, ENDOCR-RELAT CANCER, V24, pR13, DOI 10.1530/ERC-16-0432
- Qu H, 2015, CLIN ENDOCRINOL, V83, P124, DOI 10.1111/cen.12583
- Ruel E, 2015, J CLIN ENDOCR METAB, V100, P1529, DOI 10.1210/jc.2014-4332
- Sacks W, 2010, THYROID, V20, P1235, DOI 10.1089/thy.2009.0455
- So YK, 2018, INT J SURG, V50, P94, DOI 10.1016/j.ijsu.2017.12.029
- Sun W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139021
- Wiltshire JJ, 2016, THYROID, V26, P1541, DOI 10.1089/thy.2016.0100
- Yi DD, 2017, ONCOTARGET, V8, P7148, DOI 10.18632/oncotarget.12698
- Zheng W, 2019, NUCL MED COMMUN, V40, P477, DOI 10.1097/MNM.0000000000000991